NASDAQ:MGEN Miragen Therapeutics - MGEN Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$25.21▼$26.0150-Day Range$14.34▼$23.0152-Week Range$4.66▼$34.05Volume763,115 shsAverage Volume134,027 shsMarket Capitalization$99.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileFinancialsInsider TradesInstitutional OwnershipSEC FilingsShort InterestSocial Media About Miragen Therapeutics (NASDAQ:MGEN) StockMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGEN Stock News HeadlinesJanuary 19, 2021 | finance.yahoo.commiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership TeamDecember 17, 2020 | finance.yahoo.commiRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye DiseaseApril 2, 2023 | Vantage Point (Ad)What To Do With Your Trades TodayThere’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts November 10, 2020 | seekingalpha.comMiragen Therapeutics EPS beats by $0.03November 10, 2020 | finance.yahoo.commiRagen Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatesNovember 9, 2020 | finance.yahoo.comIovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in FocusNovember 1, 2020 | bloomberg.comMiragen Therapeutics IncOctober 30, 2020 | seekingalpha.comMiRagen Therapeutics shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91MApril 2, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.October 29, 2020 | finance.yahoo.comLooking Into Miragen Therapeutics's Return On Capital EmployedOctober 28, 2020 | benzinga.comLooking Into Miragen Therapeutics's Return On Capital EmployedOctober 28, 2020 | benzinga.comWhy Miragen's Stock Is Trading Higher TodayOctober 28, 2020 | seekingalpha.comMiRagen Therapeutics (MGEN) shares skyrocket 156% on Viridian acquisition, inks PIPE deal for $91MOctober 28, 2020 | finance.yahoo.commiRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.October 17, 2020 | finance.yahoo.commiRagen Announces Internal Review of Preliminary Topline Data for the Phase 2 SOLAR Clinical Trial of Cobomarsen in Patients with Cutaneous T-Cell Lymphoma (CTCL)October 6, 2020 | benzinga.comMid-Day Market Update: Crude Oil Rises Over 3%; Miragen Therapeutics Shares SlideOctober 5, 2020 | seekingalpha.comMiRagen's cobomarsen short of the mark in mid-stage blood cancer studySeptember 14, 2020 | seekingalpha.commiRagen names new CEO; to review portfolioSeptember 14, 2020 | finance.yahoo.commiRagen Announces Leadership Transition and Review of Strategic AlternativesAugust 24, 2020 | finance.yahoo.comHow Should Investors React To Miragen Therapeutics' (NASDAQ:MGEN) CEO Pay?August 24, 2020 | finance.yahoo.comHow Should Investors React To Miragen Therapeutics' (NASDAQ:MGEN) CEO Pay?August 20, 2020 | finance.yahoo.commiRagen Announces Results of Meeting With FDA Regarding the Design of Pivotal Trial for Cobomarsen in ATLLAugust 5, 2020 | seekingalpha.commiRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2020 Results - Earnings Call TranscriptAugust 5, 2020 | finance.yahoo.comSignal Genetics, Inc. (MGEN) Reports Q2 Loss, Misses Revenue EstimatesAugust 5, 2020 | seekingalpha.comMiragen Therapeutics EPS beats by $0.05, misses on revenueAugust 5, 2020 | finance.yahoo.commiRagen Reports Second Quarter 2020 Financial Results and Provides Business UpdatesAugust 4, 2020 | finance.yahoo.commiRagen to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceSee More Headlines Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGEN Company Calendar Last Earnings11/10/2020Today4/01/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGEN CUSIPN/A CIK1590750 Webwww.signalgenetics.com Phone720-643-5200FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,870,000.00 Net Margins-1,393.50% Pretax MarginN/A Return on Equity-141.66% Return on Assets-88.74% Debt Debt-to-Equity Ratio0.20 Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual Sales$4.46 million Price / Sales22.29 Cash FlowN/A Price / Cash FlowN/A Book Value$6.78 per share Price / Book3.75Miscellaneous Outstanding Shares3,908,000Free FloatN/AMarket Cap$99.42 million OptionableNot Optionable Beta1.66 Key ExecutivesMr. Jason A. Leverone CPA (Age 46)CPA, CFO, Sec. & Treasurer Comp: $355kDr. William Stuart Marshall Ph.D. (Age 56)Co-Founder & Sr. Technical Advisor Comp: $521kDr. Diana Escolar (Age 58)Chief Medical Officer Comp: $484.38kMs. Lee M. Rauch (Age 65)CEO & Director Dr. Jonathan Violin Ph.D. (Age 45)Pres & COO Eric N. OlsonCo-Founder & Chairman of Scientific Advisory BoardDr. Michael R. Bristow (Age 75)Co-Founder & Member of the Scientific Advisory Board Dr. Marvin H. Caruthers (Age 80)Co-Founder & Scientific Advisory Board Member Mr. Vahe Bedian Ph.D.Chief Scientific OfficerDr. Aimee L. JacksonVP of ResearchMore ExecutivesKey CompetitorsDermTechNASDAQ:DMTKGenetronNASDAQ:GTHPersonalisNASDAQ:PSNLSera PrognosticsNASDAQ:SERAEnzo BiochemNYSE:ENZView All Competitors MGEN Stock - Frequently Asked Questions How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS). What is Miragen Therapeutics' stock symbol? Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN." What is Miragen Therapeutics' stock price today? One share of MGEN stock can currently be purchased for approximately $25.44. How much money does Miragen Therapeutics make? Miragen Therapeutics (NASDAQ:MGEN) has a market capitalization of $99.42 million and generates $4.46 million in revenue each year. The medical research company earns $-41,870,000.00 in net income (profit) each year or ($20.09) on an earnings per share basis. How can I contact Miragen Therapeutics? Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.signalgenetics.com. The medical research company can be reached via phone at 720-643-5200 or via email at daniel@lifesciadvisors.com. This page (NASDAQ:MGEN) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.